Checkpoint Therapeutics, Inc. (CKPT): Price and Financial Metrics
GET POWR RATINGS... FREE!
CKPT POWR Grades
- CKPT scores best on the Growth dimension, with a Growth rank ahead of 88.95% of US stocks.
- CKPT's strongest trending metric is Growth; it's been moving up over the last 178 days.
- CKPT's current lowest rank is in the Stability metric (where it is better than 1.89% of US stocks).
CKPT Stock Summary
- For CKPT, its debt to operating expenses ratio is greater than that reported by only 0.44% of US equities we're observing.
- CKPT's price/sales ratio is 252.68; that's higher than the P/S ratio of 98.54% of US stocks.
- The volatility of CHECKPOINT THERAPEUTICS INC's share price is greater than that of 97.67% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to CHECKPOINT THERAPEUTICS INC are UTSI, HGEN, CLLS, RVMD, and ARAV.
- CKPT's SEC filings can be seen here. And to visit CHECKPOINT THERAPEUTICS INC's official web site, go to www.checkpointtx.com.
CKPT Valuation Summary
- CKPT's price/earnings ratio is -0.5; this is 102.21% lower than that of the median Healthcare stock.
- Over the past 70 months, CKPT's price/earnings ratio has gone up 10.7.
Below are key valuation metrics over time for CKPT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CKPT | 2023-03-17 | 253.0 | -25.4 | -0.5 | -0.2 |
| CKPT | 2023-03-16 | 276.9 | -27.8 | -0.5 | -0.2 |
| CKPT | 2023-03-15 | 264.9 | -26.6 | -0.5 | -0.2 |
| CKPT | 2023-03-14 | 270.9 | -27.2 | -0.5 | -0.2 |
| CKPT | 2023-03-13 | 266.4 | -26.7 | -0.5 | -0.2 |
| CKPT | 2023-03-10 | 291.8 | -29.3 | -0.5 | -0.3 |
CKPT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CKPT has a Quality Grade of D, ranking ahead of 20.58% of graded US stocks.
- CKPT's asset turnover comes in at 0.005 -- ranking 410th of 682 Pharmaceutical Products stocks.
- VBIV, COLL, and ARWR are the stocks whose asset turnover ratios are most correlated with CKPT.
The table below shows CKPT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.005 | 1 | 4.869 |
| 2021-03-31 | 0.004 | 1 | 4.383 |
| 2020-12-31 | 0.033 | 1 | 3.944 |
| 2020-09-30 | 0.037 | 1 | 3.435 |
| 2020-06-30 | 0.061 | 1 | 3.348 |
| 2020-03-31 | 0.117 | 1 | 3.498 |
CKPT Price Target
For more insight on analysts targets of CKPT, see our CKPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $15.80 | Average Broker Recommendation | 1.4 (Strong Buy) |
CKPT Stock Price Chart Interactive Chart >
CKPT Price/Volume Stats
| Current price | $3.82 | 52-week high | $19.10 |
| Prev. close | $3.57 | 52-week low | $3.52 |
| Day low | $3.65 | Volume | 115,500 |
| Day high | $3.95 | Avg. volume | 214,831 |
| 50-day MA | $5.17 | Dividend yield | N/A |
| 200-day MA | $8.59 | Market Cap | 35.53M |
Checkpoint Therapeutics, Inc. (CKPT) Company Bio
Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Latest CKPT News From Around the Web
Below are the latest news stories about CHECKPOINT THERAPEUTICS INC that investors may wish to consider to help them evaluate CKPT as an investment opportunity.
Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell CarcinomaPrescription Drug User Fee Act (“PDUFA”) goal date of January 3, 2024 FDA indicates that it does not currently plan to hold an advisory committee meeting WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for filing the Biologics License Application (“BLA”) for cosibelimab, Checkpoint’s investiga |
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesWALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 1,428,572 shares of its common stock (or common stock equivalents) at a purchase price of $5.25 per share of common stock (or common stock equivalent) in a registered direct offering priced at-the-market under Nasdaq ru |
Checkpoint Therapeutics to Participate in the B. Riley Securities’ 3rd Annual Oncology ConferenceWALTHAM, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities’ 3rd Annual Oncology Conference, taking place on Wednesday, January 18, 2023, at 11:00 a.m. EST. For more information and to register for the conference, please click here. A replay of the |
Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell CarcinomaPositive and clinically meaningful pivotal clinical results announced in 2022 in both metastatic and locally advanced indicationsWALTHAM, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the submission of a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for the approval of cosibelimab, its investigational anti-PD-L1 antibody, a |
Individual investors in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) are its biggest bettors, and their bets paid off as stock gained 36% last weekEvery investor in Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT ) should be aware of the most powerful shareholder... |
CKPT Price Returns
| 1-mo | N/A |
| 3-mo | 0.26% |
| 6-mo | -63.96% |
| 1-year | -79.13% |
| 3-year | -69.92% |
| 5-year | -91.77% |
| YTD | -25.24% |
| 2022 | -83.57% |
| 2021 | 17.36% |
| 2020 | 54.07% |
| 2019 | -5.49% |
| 2018 | -53.09% |
Continue Researching CKPT
Here are a few links from around the web to help you further your research on Checkpoint Therapeutics Inc's stock as an investment opportunity:Checkpoint Therapeutics Inc (CKPT) Stock Price | Nasdaq
Checkpoint Therapeutics Inc (CKPT) Stock Quote, History and News - Yahoo Finance
Checkpoint Therapeutics Inc (CKPT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...